One-hour paclitaxel via weekly infusion: Dose-density with enhanced therapeutic index

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 19-22

  Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL;

EID: 0031914962     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Lopes NM, Adams EF, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993.
2. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel in human tumor cell lines. Br J Cancer 68:1104-1109, 1993.
3. Seidman AD, Hochhauser D, Gollub MN, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study I metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
4. Chang AY, Boros L, Garrow R, et al: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22 (suppl 6), 124-127, 1995.
5. Gilewski T, Norton L: Cytokinetics and breast cancer chemotherapy in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Disease of the Breast. Philadelphia, Lippincott-Raven, 1996.
6. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997
7. Hainsworth JD, Raefsky EL, Greco FA: Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules. Cancer J Sci Am 1:281-287, 1995.
8. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Res Rep 71:53-59, 1987.
9. Huizing MT, Keung ACF, Rosin H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993.
10. 2 in pretreated patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 16:163a, 1997.
11. Wu-Wong J, Chiou W, Han E, et al: Effects of paclitaxel on cell proliferation, apoptosis and angiogenesis. Proc Am Assoc Cancer Res 38:531, 1997.
12. Torres KE, Castillo G, Horwitz SB: Induction of apoptosis by low concentrations of Taxol is not dependent on a G2/M block. Proc Am Assoc Cancer Res 38.530, 1997.